Psychedelic compounds such as LSD and Psilocybin have historically been classified alongside illicit substances and widely regarded with skepticism. However, emerging neuroscientific evidence suggests that certain psychedelics may function as “psychoplastogens”- compounds capable of promoting structural and functional neural plasticity. Recent preclinical and early clinical studies indicate that these substances can stimulate synaptogenesis, increase dendritic spine density, and enhance the expression of neurotrophic factors such as BDNF, processes that are known to decline with aging. This raises the possibility that psychedelics may play a role in preserving or restoring neuroplasticity in adulthood and old age. This article reviews current evidence regarding dose-dependent effects of psychedelics on the brain across different stages of life, with particular attention to aging-related neurobiological changes. It further explores experimental findings alongside emerging theoretical perspectives, including hypotheses at the intersection of evolutionary psychology and neurodevelopment. While promising, these findings remain preliminary, and careful longitudinal research is required to determine the safety, efficacy, and long-term implications of psychedelic-assisted interventions in aging populations.
Somkin Kyrylo (Sat,) studied this question.